The US Food and Drug Administration has approved Abbott’s Proclaim XR spinal cord stimulation (SCS) system for the treatment of patients with diabetic peripheral neuropathy (DPN).
Diabetic neuropathy is the most common side effect of diabetes, affecting as many as half of patients with the condition. There are currently no disease-modifying therapies for DPN, only symptom management and behavioral modifications to mitigate further nerve damage.
The Proclaim XR SCS system delivers low-intensity electrical impulses to nerve structures and includes a battery that lasts up to 10 hours without recharging when used at low-dose settings. Following implantation of the device, patients will have the ability to control their therapy through an Apple device. Patients can also access the manufacturer’s NeuroSphere Virtual Clinic through their mobile device, which allows them to communicate with their clinician and receive remote adjustments to their therapeutic settings as needed.